Nanoparticulate carriers for drug delivery to the brain

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 527-547

  Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NANO PARTICULATES;

DRUG DELIVERY;

EID: 84967387088     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0024     Document Type: Chapter

References (72)

1. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: The problems and possibilities. Pharmacol Ther 104:29-15.
2. Brightman M (1992) Ultrastructure of the brain endothelium. Bradbury MWB (ed.) Physiology and Pharmacology of the Blood-Brain Barrier. Handbook of Experimental Pharmacology 103 Springer: Berlin, Heidelberg, pp. 1-22.
3. Begley DJ (1996) The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48:136-146.
4. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Del 47:65-81.
5. Kreuter J (2002) Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem - Central Nervous Syst Agents 2:241-249.
6. Begley DJ and Brightman MW (2003) Structural and functional aspects of the blood-brain barrier. Prokai L and Prokai-Tatrai K (eds.) Peptide Transport and Delivery into the Central Nervous System. Progress in Drug Delivery. 61 Birkhäuser Verlag: Basel, pp. 39-78.
7. Rapoport SI (1996) Modulation of the blood-brain barrier permeability. J Drug Targ 3: 417-425.
8. Dehouck B, Fenart L, Dehouck M-P, Pierce A, Torpier G and Cecchelli R (1997) A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier J Cell Biol 138:877-889.
9. Gummerloch MK and Neuwelt EA (1992) Drug entry into the brain and its pharmacologic manipulation. Bradbury MWB (ed.) Physiology and Pharmacology of the Blood-Brain Barrier. Handbook of Experimental Pharmacology. 103 Springer: Berlin, Heidelberg, pp. 525-542.
10. Remsen LG, Trail PA, Hellstrom I, Hellstrom KE and Neuwelt EA (2000) Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 46:704-709.
11. Pardridge WM, Buciak JL and Friden PM (1991) Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 259: 66-70.
12. Huwyler J, Wu D and Pardridge WP (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci 93:14164-14169.
13. Zhou X and Huang L (1992) Targeted delivery of DANN by liposomes and polymers. J Control Rel 19:269-274.
14. Chen D and Lee KH (1993) Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system. Biochem Biophys Acta 1158:244-250.
15. Kreuter J (1994) Nanoparticles. Swarbrick J and Boylan JC (eds.) Encyclopedia of Pharmaceutical Technology. 10 Marcel Dekker: New York, pp. 165.
16. Birrenbach G and Speiser PP (1976) Polymerized micelles and their use as adjuvants in immunology. J Pharm Sci 65:1763-1766.
17. H. Kopf H, Joshi RK, Soliva M and Speiser PP (1976) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 1. Herstellung und Isolierung der Nanopartikel, Restmonomerenbestimmung, physikalisch-chemische Daten. Pharm Ind 38:281-284.
18. Alyautdin R, Gothier D, Petrov V, Kharkevich D and Kreuter J (1995) Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 41:44-48.
19. Kreuter J, Alyautdin RN, Kharkevich DA and Ivanov AA. (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171-174.
20. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-De Campenere D and Speiser P (1983) Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 15:335-345.
21. Schroeder U and Sabel BA (1996) Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 710: 121-124.
22. Ramge P, Kreuter J and Lemmer B (1999) Circadian phase-dependent antinociceptive reaction in mice after i. v. injection of dalargin-loaded nanoparticles determined by the hot-plate test and the tail-flick test. Chronobiol Int 17:767-777.
23. Tröster SD, Müller U and Kreuter J(1990) Modification of the body distribution of poly(methyl methacrylate) nanoparticles by coating with surfactants. Int J Pharm 61: 85-100.
24. Kreuter J, Petrov VE, Kharkevich DA and Alyautdin RN (1997). Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Rel 49: 81-87.
25. 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sciences 66:495-502.
26. Alyautdin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J and Begley DJ (2001) Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain-barrier in vivo and in vitro. J Drug Targ 9:209-221.
27. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY and Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles Pharm Res 16:1564-1569.
28. Couvreur P, Kante B, Grislain L, Roland M and Speiser P (1982) Toxicity of polyalkyl-cyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J Pharm Sci 71: 790-792.
29. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O and Gasco MR (1999) Pharmacokinetics of doxorubicin incorporated into solid lipid nanospheres (SLN). Pharmacol Res 40:281-286.
30. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O and Gasco MR (2002) Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 91:1324-1333.
31. Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O and Gasco MR (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II - Tissue distribution. Pharmacol Res 43:497-502.
32. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW and Yang CZ (1999) Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 59:299-307.
33. Wang JX and Zhang ZR (2002) Enhanced brain targeting by synthesis 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Biopharm 54:285-290.
34. Lockman PR, Koziara J, Roder, KE, Paulson J, Abbruscato TJ, Mumper RJ and Allen DD (2003) In vitro and in vivo assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm Res 20:705-713.
35. Lockman PR, Oyewumi MO, Koziara J, Roder, KE, Paulson J, Mumper RJ and Allen DD (2003) Brain uptake of thiamine-coated nanoparticles. J Control Rel 93:271-282.
36. Koziara MJ, Lockman PR, Allen DD and Mumper RJ (2003) In situ blood-brain barrier transport of nanoparticles. Pharm Res 20:1772-1778.
37. Koziara MJ, Lockman PR, Allen DD and Mumper RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Rel 99:259-269.
38. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V and Langer R (1994) Biodegradable long-circulating polymeric particles Science 263:1600-1603.
39. Bazile D, Prud’Homme C, Bassoullet M-T, Marlard M, Spenlehauer G and Veillard M (1995) J Pharm Sci 84:493-498.
40. Peracchia MT, Fattal E, Deasmaele D, Besnard M, Noel JP, Gomis JM, Appel M, D’Angelo J and Couvreur P (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intrave nous administration and splenic targeting. J Control Rel 60:121-128.
41. Calvo P, Gouritin B, Chacun H, Desmaele D, D’Angelo J, Noel J-P, Georgin D, Fatal E, Andreux P and Couvreur P (2001) Long-circulating PEGylated poly cyanoacrylate nanoparticles as new drug cariers for brain delivery. Pharm Res 18:1157-1166.
42. Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe M-J, Couvreur P and Vassal G (2002) Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 303:928-936.
43. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP and Gasco MR (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 42:337-343.
44. Zara GP, Cavalli R, Bargoni A, Fundarò A, Vighetto D and Gasco MR (2002) Intravenous administration of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentration of stealth agent: Pharmacokinetics and distribution in brain and other tissue. J Drug Targ 10:327-335.
45. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA and Kreuter J (1997) Delivery of loperamide across the blood-brain barrier with poly-sorbate 80-coated poly-butylcyanoacrylate nanoparticles. Pharm Res 14:325-328.
46. Schroeder U, Sommerfeld P, Ulrich S and Sabel BA. (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87:1305-1307.
47. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ and Kreuter J (1998) Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: An in situ brain perfusion study. J Microencapsul 15:67-74.
48. Friese A, Seiler E, Quack G, Lorenz B and Kreuter J (2000) Enhancement of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release delivery system. Eur J Pharm Biopharm 49:103-109.
49. Friese A. (2000) Kleinpartikuläre Trägersysteme (Nanopartikel) als ein parenterales Arzneistoff-transportsystem zur Verbesserung der Bioverfügbarkeit ZNS-aktiver Substanzen dargestellt am Beispiel der NMDA-Rezeptor-Antagonisten MRZ 2/576 und MRZ 2/596. Ph.D. Thesis, JW Goethe-Universität Frankfurt, Frankfurt.
50. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C Klein C, Andreux P and Couvreur P (2002) Quantification and localization of PEGylated polycyanoacylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 15:1317-1326.
51. Merdio M, Irache JM, Eclancher F, Mirshadi M and Villarroya H (2000) Distribution of albumin nanoparticles in animals induced with the experimental allergic encephalomyelitis. J Drug Targ 8:289-303.
52. Ueda M and Kreuter J (1997) Optimization of the preparation of loperamide-loaded poly(L-lactide) nanoparticles by high pressure emulsification-solvent evaporation. J Microencapsul 5:593-605.
53. Ueda M, Iwata A and Kreuter J (1998) Influence of the preparation methods on the drug release behaviour of loperamide-loaded nanoparticels. J Microencapsul 15:361-372.
54. Darius J, Meyer FP, Sabel BA and Schroeder U (2000) Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol 52:1043-1047.
55. Yang S, Zhu J, Lu Y and Yang C (1999) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751-757.
56. Schroeder U, Sommerfeld P and Sabel BA (1998) Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 19:777-780.
57. DeAngelis LM (2001) Brain Tumors. New Engl J Med 344:114-123.
58. Steiniger SCJ, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD and Gelperina SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759-764.
59. Donelli MG, Zucchetti M and D’Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251-260.
60. Brigger I, Morizet J, Laudani L, Aubert G, Appel M, Velasco V, Terrier-Lacombe M-J, Desmaele D, d’Angelo J, Couvreur P and Vassal G (2004) Negative preclinical results with stealth® nanosphere-encapsulated doxorubicin in an orthotropic murine brain tumor model. J Control Rel 100:29-10.
61. Walz CM, Ringe K and Sabel BA. (2002) Nanoparticles in brain tumor therapy. Controlled Release Society 30th Annual Meeting Proc. Glasgow: # 630.
62. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE and Kreuter J (2002) Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 126:131-141.
63. Diehl K-H, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal J-M and van de Vorstenbosch C (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21:15-23.
64. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C and Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Targ 10:317-325.
65. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H and Begley DJ (2003) Direct evidence that polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drugs to the nanoparticles. Pharm Res 20:409-416.
66. Olivier J-C, Fenart L, Chauvet R, Pariat C, Cecchelli R and Couet W (1999) Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 16:1836-1842.
67. San W, Xie C, Wand H and Hu Y (2004) Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomater 25:3065-3071.
68. Borchard G, Audus KL, Shi F and Kreuter J (1994) Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 110:29-35.
69. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J and von Briesen H (2000) Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capillary endothelial cells. Eur J Neurosci 12:1931-1940.
70. Lück M (1997) Plasmaproteinadsorption als möglicher Schliisselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. Ph.D. Thesis, Freie Universität Berlin, pp. 14-24, 137-154.
71. Gessner A, Olbrich C, Schröder W, Kayser O and Müller RH (2001) The role of plasma proteins in brain targeting: Species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm 214:87-91.
72. Gutman RL, Peacock G and Lu DR (2000) Targeted drug delivery for brain cancer treatment. J Control Rel 65:31-41.